Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
APTX

Aptinyx

$3.62

-0.2 (-5.24%)

07:30
04/18/19
04/18
07:30
04/18/19
07:30
Hot Stocks
Aptinyx sees initiating Phase 2 NYX-2925 study in 2H19 »

Aptinyx highlighted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

Over a week ago
APTX

Aptinyx

$4.12

0.04 (0.98%)

07:36
04/03/19
04/03
07:36
04/03/19
07:36
Hot Stocks
Aptinyx announces preclinical NYX-458 data »

Aptinyx announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APTX

Aptinyx

$4.15

-0.13 (-3.04%)

07:12
03/28/19
03/28
07:12
03/28/19
07:12
Hot Stocks
Aptinyx to present detailed results from Phase 2 NYX-2925 at APSS meeting »

Aptinyx announced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
APTX

Aptinyx

$4.03

0.03 (0.75%)

07:49
03/22/19
03/22
07:49
03/22/19
07:49
Recommendations
Aptinyx analyst commentary at BMO Capital »

Aptinyx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APTX

Aptinyx

$4.03

0.03 (0.75%)

07:25
03/22/19
03/22
07:25
03/22/19
07:25
Recommendations
Aptinyx analyst commentary at Cantor Fitzgerald »

Aptinyx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APTX

Aptinyx

$4.00

-0.1 (-2.44%)

07:15
03/21/19
03/21
07:15
03/21/19
07:15
Earnings
Aptinyx reports Q4 EPS (42c), consensus (50c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

APTX

Aptinyx

$5.64

-0.07 (-1.23%)

07:29
02/19/19
02/19
07:29
02/19/19
07:29
Hot Stocks
Aptinyx doses first patient in Phase 2 NYX-783 study »

Aptinyx announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a quarter ago
APTX

Aptinyx

$5.36

-0.62 (-10.37%)

08:22
01/18/19
01/18
08:22
01/18/19
08:22
Recommendations
Aptinyx analyst commentary at BMO Capital »

Aptinyx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APTX

Aptinyx

$5.98

-11.78 (-66.33%)

07:51
01/17/19
01/17
07:51
01/17/19
07:51
Recommendations
Aptinyx analyst commentary at Leerink »

Aptinyx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APTX

Aptinyx

$5.98

-11.78 (-66.33%)

04:55
01/17/19
01/17
04:55
01/17/19
04:55
Downgrade
Aptinyx rating change at JPMorgan »

Aptinyx downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.